HIGHLIGHTS
- who: Albert Qin et al. from the University of Bern, Switzerland have published the research work: An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future, in the Journal: (JOURNAL)
- what: The Phase 1 portion of the study aimed to identify the maximum tolerated dose (MTD) of ropeginterferon alfa2b in 25 patients using a 3 + 3 dose-escalation method. The Phase 2 portion of the PEGINVERA study was designed to assess efficacy in the form of complete response . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.